Pages that link to "Q72593257"
Jump to navigation
Jump to search
The following pages link to Jitters jeopardize AIDS vaccine trials (Q72593257):
Displaying 35 items.
- Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1 (Q27639371) (← links)
- Some important issues in the planning of phase III HIV vaccine efficacy trials (Q30233733) (← links)
- "Negative vaccination" by specific CD4 T cell tolerisation enhances virus-specific protective antibody responses (Q33305432) (← links)
- CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. (Q33783578) (← links)
- Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1 (Q33786049) (← links)
- Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition (Q33850612) (← links)
- Turning a corner on HIV neutralization? (Q33878662) (← links)
- Antibodies in human infectious disease. (Q33942081) (← links)
- Assessment of HIV vaccine development: past, present, and future (Q34050712) (← links)
- Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. (Q35365474) (← links)
- Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera (Q35828529) (← links)
- A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. (Q35828898) (← links)
- Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies (Q35848446) (← links)
- Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. (Q35853750) (← links)
- Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies (Q35854001) (← links)
- Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules (Q35859319) (← links)
- In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope (Q35874414) (← links)
- A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays (Q36363866) (← links)
- Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope (Q36549107) (← links)
- Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 (Q36625449) (← links)
- Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization (Q36635390) (← links)
- Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design (Q36872332) (← links)
- Erratum to “Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design” [Immunol. Lett. 57 (1997) 105–112] (Q36879170) (← links)
- Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni (Q39243308) (← links)
- Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. (Q39313957) (← links)
- The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain (Q39439112) (← links)
- Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate (Q39603619) (← links)
- Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. (Q39610187) (← links)
- Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. (Q39868309) (← links)
- Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. (Q39879382) (← links)
- Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. (Q40038277) (← links)
- Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. (Q40626990) (← links)
- Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. (Q43872744) (← links)
- Neutralization tiers of HIV-1. (Q47562235) (← links)
- Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen (Q71848107) (← links)